# Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

> **NCT00005869** · PHASE3 · UNKNOWN · sponsor: **Astex Pharmaceuticals, Inc.**

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **DRUG:** rubitecan

## Key facts

- **NCT ID:** NCT00005869
- **Lead sponsor:** Astex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1998-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005869, "Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00005869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*